|
|
Article: GenPath Raises $15.5M In Series A To Study Cancer Genes, Pathways.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
GenPath Pharmaceuticals Inc. plans to take aim at cancer and other genetic diseases with $15.5 million it raised in a Series A financing.
The company was founded by Harvard Medical School researchers Ronald DePinho and Lynda Chin. GenPath said its technology also is applicable to cardiovascular disease and metabolic and neurodegenerative disorders.
Interim President and board member Ken Weg, former vice chairman of Bristol-Myers Squibb Co., of New York, told BioWorld Today the money should take the company through about 18 months.
"How far the money takes us depends on the progress we make with our validated targets," Weg ...